ArticleCureus2021
Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer.
Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Immune checkpoint inhibitor- and phosphatidylinositol-3-kinase inhibitor-related diabetes induced by antineoplastic drugs: two case reports and a literature review.Frontiers in endocrinology · 2023Pooled it
- Determinants of diabetic ketoacidosis among adults with diabetes mellitus at the Ambo town Hospitals, Ethiopia.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the case of a 45-year-old woman with metastatic breast cancer who started treatment with alpelisib nine days before developing diabetic ketoacidosis (DKA). At the time of DKA diagnosis, blood tests showed a capillary blood glucose of 30 mmol/L, serum carbon dioxide level of 11 mmol/L, an anion gap of 25 mEq/L, and a glycated hemoglobin A1C (HbA1c) level of 6.4% (50 mmol/mol). Her HbA1C on admission was 5.6% (38 mmol/mol). Capillary blood glucose levels improved upon discontinuation of alpelisib and returned to baseline four days after drug discontinuation. DKA is a rare but serious adverse effect of alpelisib. Patients on this medication should be closely monitored for hyperglycemia and DKA. Further studies are needed to help identify patients at risk of hyperglycemia and DKA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.